KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

GoodRx Holdings (GDRX) Other Operating Expenses (2019 - 2026)

GoodRx Holdings' Other Operating Expenses history spans 7 years, with the latest figure at $119.2 million for Q4 2025.

  • On a quarterly basis, Other Operating Expenses fell 4.71% to $119.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $474.4 million, a 2.16% decrease, with the full-year FY2025 number at $470.2 million, down 2.12% from a year prior.
  • Other Operating Expenses hit $119.2 million in Q4 2025 for GoodRx Holdings, up from $118.4 million in the prior quarter.
  • Over the last five years, Other Operating Expenses for GDRX hit a ceiling of $152.5 million in Q4 2023 and a floor of -$47.9 million in Q4 2021.
  • Historically, Other Operating Expenses has averaged $73.9 million across 5 years, with a median of $114.1 million in 2023.
  • Biggest five-year swings in Other Operating Expenses: crashed 154.05% in 2021 and later surged 7834.74% in 2023.
  • Tracing GDRX's Other Operating Expenses over 5 years: stood at -$47.9 million in 2021, then surged by 95.88% to -$2.0 million in 2022, then surged by 7834.74% to $152.5 million in 2023, then fell by 17.97% to $125.1 million in 2024, then dropped by 4.71% to $119.2 million in 2025.
  • Business Quant data shows Other Operating Expenses for GDRX at $119.2 million in Q4 2025, $118.4 million in Q3 2025, and $117.9 million in Q2 2025.